An ocular implant comprising siRNA complexed with a transfection agent selected from the group consisting of cationic lipids and short cell penetration peptides, wherein the complex is associated with a biocompatible polymer is described. The biocompatible polymer comprises a polymeric matrix configured to release the complex into the eye of a patient at therapeutic levels for a time sufficient to treat an ocular condition or disease.